Table 3

Patient characteristics

Gunes et al21Marazzi et al22Belardinelli et al23Tuunanen et al24Belardinelli et al25Di Napoli et al29Sisakian et al37Di Napoli et al26Fragasso et al27
Patients (trimetazidine/placebo)87 (51/36)47 (23/24)30/2619 (12/7)35 (19/16)61 (30/31)82 (42/40)50 (25/25)55 (28/27)
Age (years) (trimetazidine/placebo)59.4±9.5/56.6±13.678±3.4/77±2.359±8/58±959±8.8/57±7.354.3±6.9/53.7±967±5.5/69±763.5±59.3/65.6±8.764±6/63±764±7/66±7
Men (N) (trimetazidine/placebo)37/2118/2225/2210/516/1317/1837/3315/1825/25
Ischaemic cause (N)35/221001000100100100%100%18/17
LVEF (%) (trimetazidine/placebo)33.3±5.6/30.6±8.2<50%35.0±7/36.6±631±8.5/38±8.439±6/40±630±6/31±834.5±3.8/32.4±5.628±4/30±634±7/36±5
NYHA classification (N)NA2.2±0.3/2.2±0.4NANANA
I07/3000
II25/1722/1018/1810/107/13
III26/1918/1024/2213/1221/13
IV0002/30/1
Diabetes (trimetazidine/placebo)14/11NA0/019/1510/11NANA1/3
β-Blocker therapy45/3416/1826/2311/715/1315/1838/4020/1921/22
ACE inhibitor or ARB47/3423/2430/2512/719/1527/2842/4024/2528/27
Digitalis33/1818/20NA4/2NA8/78/115/56/5
Aldosterone antagonist45/31NANANANA8/7NA9/1112/10
Diuretic therapy36/2323/228/77/4NA30/3123/2125/2524/22
Statins27/1920/2126/224/216/146/86/720/199/8
Fragasso et al28El-Kady et al35Vitale et al30Thrainsdottir et al31Rosano et al32Fragasso et al33Belardinelli et al34Brottier et al36
Patients (trimetazidine/placebo)12/12200 (100/100)47 (23/24)10/1032 (16/16)16/1638 (19/19)20 (9/11)
Age (years) (trimetazidine/placebo)66±552.8±8.7/53±8.777±2.3/78±4.367.1±7.2/65.7±9.065.6±5.7/65.2±764±750±7/54±757.0±3.2/61.9±0.9
Men (n, %) (trimetazidine/placebo)1186/7818/229/711/131615/1619
Ischaemic cause6100100100%100%100%100%100%
LVEF (%) (trimetazidine/placebo)33±735.6±17.1/36.9±13.929±2.2/28.7±2.833±10/29±1132.3±5.3/32.8±2.340±533±4.5/33.4±3.532.2±3.1/29.4±2.6
NYHA class2.2±0.3/2.2±0.4NANA
I3/40un0
II10/1210/8un14/13
III10/80/2un5/66
IV000014
Diabetes (trimetazidine/placebo)NA37/30NA10/1016/1616NANA
β-Blocker therapy1269/7516/1810/911//12102/30
ACE inhibitor or ARB1289/9423/1249/616/161619/180
Digitalis10NA18//200/113/1525/49
Aldosterone antagonistNANANANANA6NANA
Diuretic10NA23/228/616/151511/1115
StatinsNANA20/215/814/163NANA
  • ARB, angiotensin receptor blocker; N, number of patients; NA,unable to assess; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.